Clinical Trial Update: A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating [18F]-FDG PET imaging in patients with advanced pancreatic cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Pancreatic Adenocarcinoma | Phase 1 | Status: TERMINATED